课题基金 / 基金详情

RAPID: Responsible conduct of accelerated SARS-CoV-2 vaccine research through challenge trials

RAPID: Responsible conduct of accelerated SARS-CoV-2 vaccine research through challenge trials
RAPID:通过挑战试验负责任地加速 SARS-CoV-2 疫苗研究
批准号:
2039320
负责人:
Nir Eyal
金额:
$20.0万
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-08-01 至 2021-07-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This project examines the ethics of accelerating research into a COVID-19 vaccine through human challenge trials. In a human challenge trial, healthy volunteers are deliberately exposed to the virus after being given the vaccine (or placebo). The project examines the ethics of these trials and how to make them more ethical through philosophical research and through a survey of challenge trial volunteers. While even the most ethically conducted challenge trial will involve risks to volunteers, these trials can also accelerate the development of a vaccine for COVID-19 by several months. Given the current rates of infection and mortality, this time gain could translate into many thousands of lives being saved. Findings will also benefit humanity in future public health crises where quick testing of vaccine efficacy is needed. Dissemination of the findings will promote public scientific literacy, and deepened engagement with science, ethics, and technology across STEM disciplines. Clarifying these ethical principles will facilitate more efficient partnerships between government, academia, industry, and others, and promote national security via increased resilience to pandemics, biological warfare, and other threats. This project uses multiple methods to investigate the ethics of human challenge trials for COVID-19. It has three main research components: 1) a philosophical examination of whether responsible conduct of challenge trials for SARS-CoV-2 is possible, under what criteria (e.g., what inclusion and exclusion criteria and trial procedures would reduce net harm to participants), and subject to what institutional oversight mechanisms (e.g., a special added IRB/expert taskforce); 2) a survey of 3,000 proactive volunteers for SARS-Cov-2 human challenge trials and a randomly selected control group about their motivations and beliefs about COVID-19 and the current pandemic, risk perceptions, and willingness to take risks; and 3) creation of an education package for trialists based on the findings. This package will educate trialists about potential pitfalls of challenge trials, such as potential misunderstanding of trial details and risk, which the informed consent process must emphasize, and avoiding unfair participant selection, which might be a pitfall given the lower socio-economic status of many high-transmission/surge areas. This project advances knowledge in several areas of STEM research ethics, including the ethics of challenge studies, the assessment of risks and benefits to participants, and the degree to which participants’ autonomous authorization of research may make even somewhat adverse risk/benefit ratios ethically tolerable.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
Reply to Hasford and to Spinola et al.
回复哈斯福德和斯皮诺拉等人。
DOI: 10.1093/infdis/jiaa458
发表时间: 2020
期刊: The Journal of infectious diseases
影响因子: --
作者: [Eyal,Nir, Lipsitch,Marc, Smith,PeterG]
通讯作者: Smith,PeterG
SARS-CoV-2 Human Challenge Studies
SARS-CoV-2 人类挑战研究
DOI: 10.1056/nejmc2113574
发表时间: 2021
期刊: New England Journal of Medicine
影响因子: 158.5
作者: []
通讯作者:
Study bystanders and ethical treatment of study participants-A proof of concept.
研究旁观者和研究参与者的道德待遇——概念证明。
DOI: 10.1111/bioe.12825
发表时间: 2020
期刊: Bioethics
影响因子: 2.2
作者: [Eyal,Nir]
通讯作者: Eyal,Nir
Is There an Ethical Upper Limit on Risks to Study Participants?
研究参与者的风险是否有道德上限?
DOI: 10.1093/phe/phaa028
发表时间: 2020
期刊: Public health ethics
影响因子: 2.1
作者: [Eyal,Nir]
通讯作者: Eyal,Nir
9
    海外基金